Tandem Diabetes Care (TNDM) is back in focus after announcing that its t:slim X2 insulin pump with Control-IQ+ technology now works with Abbott’s FreeStyle Libre 3 Plus CGM across five European countries.

The Abbott compatibility news arrives after a period where Tandem Diabetes Care’s share price has weakened, with a 30 day share price return down 7.17% and a 90 day share price return down 27%, while the 1 year total shareholder return is down 2.16%. This points to fading momentum despite ongoing product expansion.

If you are looking beyond Tandem Diabetes Care for other healthcare technology opportunities, this is a good moment to scan 40 healthcare AI stocks for potential ideas that fit your watchlist.

Recent weakness in Tandem Diabetes Care’s share price contrasts with continued product rollouts. This leaves a key issue on the table: are investors reassessing the business fundamentals, or simply rotating away on sentiment as the current valuation stands?

Most Popular Narrative: 47.2% Undervalued

The most followed valuation narrative for Tandem Diabetes Care points to a fair value of $29.20 against a last close of $15.41, framing the stock as materially discounted based on long term earnings and cash flow assumptions.

Advancements in product pipeline including the upcoming launches of Steadiset extended wear infusion sets and Tubeless Mobi reinforce innovation leadership and enable participation in the sustained shift toward automated, user friendly pump solutions, which will support both topline growth and gross margin expansion.

Want to see what sits behind that confidence in Tandem Diabetes Care? The core of this narrative is a step change in revenue, profitability, and the multiple investors might one day pay for those earnings. Curious which specific growth and margin assumptions have to hold for a $29.20 fair value to make sense? The full narrative lays out the exact road map behind those numbers.

Result: Fair Value of $29.20 (UNDERVALUED)

However, Tandem Diabetes Care still faces pressure from intensifying competition and execution risk around its pharmacy and international expansion, which could challenge the bullish earnings narrative.

Next Steps

With a mix of concerns and optimism around Tandem Diabetes Care, this is a moment to move quickly and test the narrative against the numbers for yourself, starting with the balance of 3 key rewards and 1 important warning sign

Looking for more investment ideas beyond Tandem Diabetes Care?

If you stop with Tandem Diabetes Care, you miss other stocks that may better fit your goals. Broaden your hunting ground with targeted screeners today.

• Spot potential value opportunities early by scanning companies highlighted in the 45 high quality undervalued stocks that may trade at prices below their assessed fundamentals.
• Strengthen your focus on financial resilience by checking stocks featured in the solid balance sheet and fundamentals stocks screener (47 results) that pair sturdy balance sheets with underlying business quality.
• Get ahead of the crowd by reviewing the screener containing 19 high quality undiscovered gems that surfaces stocks with solid fundamentals that many investors may be overlooking.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.